Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study(1)(2)(3)

Background: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related comorbiditie...

Descripción completa

Detalles Bibliográficos
Autores principales: Garvey, W Timothy, Ryan, Donna H, Look, Michelle, Gadde, Kishore M, Allison, David B, Peterson, Craig A, Schwiers, Michael, Day, Wesley W, Bowden, Charles H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Nutrition 2012
Materias:
Obesity and Eating Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260065/
https://www.ncbi.nlm.nih.gov/pubmed/22158731
http://dx.doi.org/10.3945/ajcn.111.024927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260065/
https://www.ncbi.nlm.nih.gov/pubmed/22158731
http://dx.doi.org/10.3945/ajcn.111.024927

Ejemplares similares